Drug search by name

Tigecycline Intravenous and Liver disease

Generic Name: tigecycline
Dosage Forms: n.a.
Other Brand Names: Tygacil

Result of checking the interaction of drug Tigecycline Intravenous and disease Liver disease for safety when used together.

Check result:

Tigecycline Intravenous <> Liver disease

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Tigecycline is primarily metabolized by the liver and excreted in the bile as unchanged drug and metabolites. In a single-dose study of subjects with varying degrees of hepatic impairment, systemic clearance of tigecycline was reduced by 25% and half-life prolonged by 23% in patients classified as having moderate hepatic impairment (Child Pugh B) compared to age- and weight-matched healthy control subjects. In patients with severe hepatic impairment (Child Pugh C), systemic clearance of tigecycline was reduced by 55% and half-life prolonged by 43% compared to controls. No significant pharmacokinetic changes were reported in patients with mild hepatic impairment (Child Pugh A). Therapy with tigecycline should be administered cautiously in patients with severe liver disease. The initial dose should be 100 mg followed by a reduced maintenance dose of 25 mg every 12 hours. No dosage adjustment is necessary in patients with mild to moderate hepatic impairment.

References: